The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients
- 20 November 2003
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 42 (10) , 1757-1763
- https://doi.org/10.1016/j.jacc.2003.04.001
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Structure, Endothelial Function, Cell Growth, and Inflammation in Blood Vessels of Angiotensin II–Infused RatsCirculation, 2002
- Inflammation and AtherosclerosisCirculation, 2002
- Immune Mechanisms in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Circulating Cell Adhesion Molecules and Death in Patients With Coronary Artery DiseaseCirculation, 2001
- Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and AtherogenesisMolecular Cell, 2001
- The Endothelium and Lipoproteins: Insights from Recent Cell Biology and Animal StudiesSeminars in Thrombosis and Hemostasis, 2000
- Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient miceJournal of Clinical Investigation, 2000
- PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDLCell, 1998
- Nuclear Factor-κB — A Pivotal Transcription Factor in Chronic Inflammatory DiseasesNew England Journal of Medicine, 1997